Search Tag: Sepsis
2025 24 Jul
Sepsis remains a leading cause of morbidity and mortality in intensive care units (ICUs), exacerbated by delays in diagnosis and inadequate risk stratification. Despite advances in critical care, conventional biomarkers like procalcitonin (PCT) and C-reactive protein (CRP) often fail to provide timely or specific detection. Pancreatic Stone Protein...Read more
2025 20 May
Sepsis remains one of the most daunting challenges in critical care. An estimated 49 million cases of sepsis occur globally every year, and it affects 1 in 5 people worldwide. Sepsis is responsible for 11 million deaths each year — this accounts for 20% of all global deaths. Sepsis and Acute Respiratory Distress Syndrome (ARDS)...Read more
2025 20 May
Sepsis and Acute Respiratory Distress Syndrome (ARDS) are heterogeneous critical illness syndromes. Molecular subphenotyping shows promise in furthering our understanding of these syndromes and may offer a more precise method for identifying appropriate therapies. Current Definitions of Sepsis and Acute Respiratory Distress Syndrome...Read more
2025 20 May
Both sepsis and Acute Respiratory Distress Syndrome (ARDS) are major determinants of morbidity and mortality in the ICU, and sepsis is often complicated by ARDS. We discuss the role of corticosteroids in these patients. Introduction Acute respiratory distress syndrome (ARDS) is a heterogeneous syndrome that can be the result of several...Read more
2025 20 May
This article highlights sepsis early recognition and prevention to reduce the risk of developing sepsis-induced ARDS while emphasising pathophysiology, early recognition, and early intervention for both conditions. Introduction Sepsis, a life-threatening condition caused by a dysregulated immune response to infection, is a preventable...Read more
2025 20 May
Sepsis-induced ARDS is a critical condition that may require anti-inflammatory strategies. There are some promising treatments that may alter the evolution, including corticosteroids, vitamin C, NET inhibitors, and statins, which help mitigate excessive immune response and improve clinical outcomes. Introduction Sepsis represents a...Read more
2025 20 May
Sepsis and ARDS are complex syndromes where point-of-care testing and biomarker-guided, personalised treatments offer growing promise. With high mortality, prolonged recovery, and emerging therapies like anti-fibrotics, even small gains may be cost-effective. Sepsis and Acute Respiratory Distress Syndrome (ARDS) are both clinical syndromes...Read more
2025 27 Mar
The basics of vasopressor support and advanced considerations regarding its early use in intensive care settings. Introduction The use of vasopressors in critical care is a crucial aspect of haemodynamic management. While norepinephrine remains the primary agent of choice, the role of other vasopressors such as vasopressin has gained...Read more
2025 19 Mar
The complexity of clinical trials in critical illness remains a significant challenge. A discussion at the ISICEM Congress in Brussels focused on why trials often fail, the role of heterogeneity in patient responses, and emerging methodologies to improve our understanding of pathways to outcomes. For over 30 years, researchers have debated...Read more
2025 18 Mar
Sepsis is a common and potentially fatal condition, causing over 270,000 deaths annually in the U.S. Emergency treatment involves fluids and vasopressors, with norepinephrine as the first-line choice and vasopressin as a second-line option when blood pressure remains unresponsive. However, the timing of vasopressin use is unclear due to the dynamic...Read more
2025 17 Feb
Vasopressors are commonly used in critically ill patients to increase vascular tone in cases of severe hypotension with signs of altered tissue perfusion, such as poor skin perfusion, altered mental status, or decreased urine output—indicative of shock. Shock is associated with elevated lactate levels (>2 mmol/L) and can be classified into four types:...Read more
2024 28 Nov
Abionic, an innovative medical diagnostics company specialising in rapid early detection technologies, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its IVD CAPSULE PSP test. Abionic, an emerging medical diagnostics company focused on rapid early detection technologies, received 510(k) clearance for...Read more
2024 28 Nov
Vasopressin timing, patient selection, optimal vasopressin use in septic shock, and potential mortality benefits in selected patient populations. Septic Shock Overview and Current Treatments Septic shock is a severe, life-threatening response to infection, characterised by systemic inflammation, tissue hypoperfusion, and persistent,...Read more
2024 14 May
Critical illness-related corticosteroid insufficiency (CIRCI) is commonly seen in criticall ill patients and involves systemic inflammation, hypothalamus–pituitary–adrenal axis dysregulation, altered cortisol metabolism, and tissue glucocorticoid resistance. A task force of international experts from the Society of Critical Care Medicine...Read more
2024 21 Apr
Sepsis is a Medical Emergency Requiring Immediate Diagnosis & Treatment Pancreatic Stone Protein (PSP) on the abioSCOPE® is the Earliest Marker of Sepsis Sepsis is a major healthcare burden claiming more than 11 million lives per year, one death every 2.8 seconds 1 . It is caused by a dysregulated host response to infection which...Read more
2024 12 Mar
An overview of landiolol, a potent and cardioselective beta-blocker offering a promising addition to the armamentarium for managing acute cardiac conditions for rapid and effective rate control with minimal adverse effects. Cardiac emergencies present complex challenges in emergency medical settings, requiring prompt and effective management...Read more
2024 20 Mar
Session One March 20, 2024 | 3:00 PM EST Session Two March 28, 2024 | 1:00 PM EST Session Three March 26, 2024 | 11:00 AM GMT Read more
2023 30 Nov
Intensive care impacts more than the patient, with ripple effects for families, employers and wider societies. Patient-centred outcomes reiterate the need for clinical therapies targeting the biological circuitry of the big-hitting syndromes like ARDS, sepsis, delirium, renal failure and recognising they persist beyond the veil of discharge....Read more
2023 30 Nov
An overview of vasopressor management, current evidence on its use, when to initiate vasopressor therapy for best possible patient outcome and a discussion regarding the use of landiolol in septic patients with persistent tachycardia. Optimising Vasopressin Initiation in Septic Shock Patients with septic shock, and especially...Read more
2023 13 Oct
Vasopressin and landiolol are critical therapies for ensuring the vascular and cardiac systems are as close to optimal conditions as possible during septic shock. Better cardiovascular management in septic shock can help improve septic shock management. Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response...Read more
2023 13 Oct
The use of Artificial Intelligence in detecting sepsis, AI prediction/detection models and how these healthcare tools need to complement clinical expertise. The potential of Artificial Intelligence (AI) in healthcare has generated significant excitement and discussion. However, it's important to distinguish between the theoretical...Read more
2023 12 Sep
A woman came to see me a few days ago: her 44-year-old husband recently died from sepsis in another hospital, and she wanted to have a discussion about this tragic story. Her husband had had just some kind of blister on his foot. He didn’t seem very ill when he arrived at the hospital, but he quickly developed an extended area of fasciitis on his left...Read more